Cameron Bozdog's questions to Cytokinetics Inc (CYTK) leadership • Q3 2024
Question
Cameron Bozdog of Bank of America questioned which factors, such as safety or efficacy, would be most critical in justifying a potential pricing premium for aficamten.
Answer
Robert I. Blum, President and CEO, clarified that the company anticipates pricing in the 'same ZIP code' as the competitor, not at a premium. Andrew Callos, EVP and CCO, added that the focus is on achieving access parity. Blum emphasized that market research indicates risk mitigation and a favorable safety profile are key to driving broader physician adoption.